T cell therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid ...

Innate immunity represents an important arm of immune response, vital to sensing damages, pathogenic or non-pathogenic, and to repair the injury tissue. It comprehends several elements including ...

30, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators ...

Chimeric antigen receptor T-cell therapy (CAR-T) has shown significant promise in the treatment of blood malignancies in the ...

Researchers found that natural killer T (NKT) cells influence whether the response generates protective antibodies that neutralise the virus or harmful ones that could exacerbate the disease in ...

About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are ...

Our findings demonstrate that CAR-NKT cells not only effectively eliminate CD1d-expressing M2-like macrophages within the tumor microenvironment but also stimulate endogenous immune cells,” said Xin ...

Oct. 9, 2024 — Researchers have developed a groundbreaking cell culture platform that enables the formation of two distinct but interconnected vascular networks. Their breakthrough holds ...

They also reported that CAR-NKT cells promoted epitope spreading—a process by which the immune system recognizes and attacks ...

Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune ...